Introducción. Hace unos 30 años se describió una enfermedad hepática semejante a la hepatitis alcohólica en sus manifestaciones. Many translated example sentences containing “esteatosis hepática no alcohólica” – English-Spanish dictionary and search engine for English translations. Resumen. La esteatosis hepática es el acúmulo de grasa en los hepatocitos, que puede ser la consecuencia del proceso de regeneración.

Author: Kajik Kataxe
Country: Nigeria
Language: English (Spanish)
Genre: Health and Food
Published (Last): 8 July 2015
Pages: 313
PDF File Size: 17.5 Mb
ePub File Size: 7.72 Mb
ISBN: 258-7-75293-965-5
Downloads: 30157
Price: Free* [*Free Regsitration Required]
Uploader: Mezirg

Desde entonces aumentan los conocimientos sobre ella. Estos receptores nucleares abundan en el tejido adiposo y existen en menor cantidad en los hepatocitos. El autor manifiesta que hay que tener en cuenta lo poco que se conoce de esta enfermedad y que los resultados de las investigaciones son conflictivos.

Otros hacen diferencia en la cantidad a ingerir de acuerdo al sexo: La obesidad y los signos de resistencia a la insulina por ej. Mayo Clinic experiences with a hitherto unnamed disease. The natural history of nonalcoholic steatohepatitis: The natural history of non-alcoholic Figure 2.

Mean scores for inflammation, ballooning necrosis, steatosis, and fibrosis in liver biopsy specimens before and after treatment with a hypocaloric diet kcal per day plus pioglitazone, or a hypocaloric diet plus placebo, in 55 patients with impaired glucose tolerance or T2DM and liver biopsy-confirmed NASH.

Between-group differences were compared by means of the Wilcoxon rank-sum test. Withingroup differences before versus after treatment were compared by means of the Wilcoxon signed-rank test. Reproduced, with permission, from Belfort R et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.

Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Nonalcoholic fatty liver disease. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Prevalence of hepatic steatosis in an urban population in the United States: Effect of body mass index on nonalcoholic fatty liver disease in patients undergoing minimally invasive bariatric surgery.

Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. The prevalence and etiology of elevated aminotransferase levels in the United States.

Natural history of nonalcoholic steatohepatitis: The histological course of nonalcoholic fatty liver disease: Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. Liver abnormalities in severely obese subjects: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Nonalcoholic fatty liver disease in severely obese subjects.


Amarapurkar D, Patel N. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease.

Maheshwari A, Paul JT.

There was a problem providing the content you requested

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular a,coholica. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Non-alcoholic fatty alcoholicx disease, the metabolic syndrome and the risk of cardiovascular disease: Relations between carotid artery wall thickness and liver histology in subjects with non-alcoholic fatty liver disease.

Molecular mediators of hepatic steatosis and liver injury. Aloholica and the pathogenesis of non-alcoholic steatohepatitis. Pessayre D, Fromenty B. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: The effect of pioglitazone on peroxisome proliferator-activated receptorgamma target genes related to lipid storage in vivo.

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non-alcoholic fatty liver disease.

The ins and outs of mitochondrial dysfunction in NASH.

Esteatosis hepática no alcohólica – Artículos – IntraMed

Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.

Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. Pioglitazone treatment activates AMPactivated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun. Adiponectin stimulates glucose utilization and fattyacid oxidation by activating AMP-activated protein kinase.

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes.

Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Adiponectin and its receptors in non-alcoholic steatohepatitis. Peroxisome proliferator- activated receptors and the control of inflammation. Curr Drug Targets Inflamm Allergy.


Pioglitazone time-dependently reduces tumour necrosis factor-a level in muscle and improves metabolic abnormalities in Wistar fatty rats. Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferatoractivated receptor-gamma, pioglitazone. J Pharmacol Exp Ther. The fluctuation of serum levels of aminotransferase in patients with non-alcoholic steatohepatitis.

Non-alcoholic steatohepatitis in type 2 diabetes mellitus. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Adams LA, Paul A. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation.

Macrovesicular hepatic steatosis in living related liver donors: The utility of radiological imaging in nonalcoholic fatty liver disease. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis.

J Magn Reson Imaging. Effects of peroxisome proliferator-activated receptor PPAR -alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Quantification of liver fat using magnetic resonance spectroscopy. Magnetic resonance spectroscopy to measure hepatic triglyceride content: Am J Physiol Endocrinol Metab.

Measurement of intracellular triglyceride stores by H spectroscopy: Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic hepxtica spectroscopy. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Diagnostic evaluation of non-alcoholic fatty liver disease.

Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting. Hepatic effects of dietary weight loss in morbidly obese subjects. Improvement in liver histological analysis with weight loss. Gastric bypass surgery improves metabolic esteatosiss hepatic abnormalities associated with nonalcoholic fatty liver disease. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Effects of bariatric surgery on mortality in Swedish obese subjects.

Long-term mortality after gastric bypass surgery. Is weight reduction an effective therapy for nonalcoholic fatty liver?

Comparative review of diets for the metabolic syndrome: Am J Clin Nutr. Palmer M, Schaffner F.